John J Suschak
Overview
Explore the profile of John J Suschak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harrison S, Browne S, Suschak J, Tomah S, Gutierrez J, Yang J, et al.
J Hepatol
. 2024 Jul;
82(1):7-17.
PMID: 39002641
Background & Aims: This was a randomized, double-blind, placebo-controlled study to assess the effects of pemvidutide, a glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist, on liver fat content (LFC) in individuals...
2.
Dickson A, Geerling E, Stone E, Hassert M, Steffen T, Makkena T, et al.
Front Immunol
. 2023 Sep;
14:1188392.
PMID: 37662899
Introduction: Vaccination is the most effective mechanism to prevent severe COVID-19. However, breakthrough infections and subsequent transmission of SARS-CoV-2 remain a significant problem. Intranasal vaccination has the potential to be...
3.
Golden J, Fitzpatrick C, Suschak J, Clements T, Ricks K, Sanchez-Lockhart M, et al.
Virus Res
. 2023 Jul;
334:199173.
PMID: 37459918
Crimean-Congo hemorrhagic fever (CCHF) is a World Health Organization prioritized disease because its broad distribution and severity of disease make it a global health threat. Despite advancements in preclinical vaccine...
4.
Schultz M, Suschak J, Botta D, Silva-Sanchez A, King R, Detchemendy T, et al.
Hum Vaccin Immunother
. 2022 Oct;
18(6):2127292.
PMID: 36194255
The coronavirus disease 2019 (COVID-19) pandemic has illustrated the critical need for effective prophylactic vaccination to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intranasal vaccination is...
5.
Nestor J, Parkes D, Feigh M, Suschak J, Harris M
Sci Rep
. 2022 Apr;
12(1):6666.
PMID: 35461369
Body weight loss of ≥ 10% improves the metabolic derangements and liver disease in the majority of non-alcoholic steatohepatitis (NASH) patients, suggesting metabolic modulators may be effective in controlling disease....
6.
Suschak J, Bixler S, Badger C, Spik K, Kwilas S, Rossi F, et al.
NPJ Vaccines
. 2022 Apr;
7(1):46.
PMID: 35459271
We have previously shown that DNA vaccines expressing codon optimized alphavirus envelope glycoprotein genes protect both mice and nonhuman primates from viral challenge when delivered by particle-mediated epidermal delivery (PMED)...
7.
King R, Silva-Sanchez A, Peel J, Botta D, Dickson A, Pinto A, et al.
Vaccines (Basel)
. 2021 Aug;
9(8).
PMID: 34452006
The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective prophylactic vaccination to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intranasal vaccination is...
8.
Suschak J, Golden J, Fitzpatrick C, Shoemaker C, Badger C, Schmaljohn C, et al.
NPJ Vaccines
. 2021 Mar;
6(1):31.
PMID: 33654101
Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Previously,...
9.
Suschak J, Dupuy L, Shoemaker C, Six C, Kwilas S, Spik K, et al.
Mol Ther Methods Clin Dev
. 2020 Apr;
17:810-821.
PMID: 32296729
DNA vaccines expressing codon-optimized Venezuelan equine encephalitis virus (VEEV) and Ebola virus (EBOV) glycoprotein genes provide protective immunity to mice and nonhuman primates when delivered by intramuscular (IM) electroporation (EP)....
10.
Suschak J, Schmaljohn C
Hum Vaccin Immunother
. 2019 Oct;
15(10):2359-2377.
PMID: 31589088
The filoviruses Ebola virus and Marburg virus are among the most dangerous pathogens in the world. Both viruses cause viral hemorrhagic fever, with case fatality rates of up to 90%....